HC Wainwright & Co. Downgrades Aldeyra Therapeutics to Neutral, Lowers Price Target to $2
Aldeyra Therapeutics, Inc. -1.12%
Aldeyra Therapeutics, Inc. ALDX | 1.76 | -1.12% |
HC Wainwright & Co. analyst Matthew Caufield downgrades Aldeyra Therapeutics (NASDAQ:
ALDX) from Buy to Neutral and lowers the price target from $10 to $2.
